Pneumococcal Bacteremia with Especial Reference to Bacteremic Pneumococcal Pneumonia
Authors: ROBERT AUSTRIAN
Journal: Annals of Internal Medicine (1964)

Article1 May 1964Pneumococcal Bacteremia with Especial Reference to Bacteremic Pneumococcal PneumoniaROBERT AUSTRIAN, M.D., JEROME GOLD, M.D.ROBERT AUSTRIAN, M.D., JEROME GOLD, M.D.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-60-5-759 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTwenty-five years have elapsed since the subject of pneumococcal bacteremia has been reviewed (1, 2). In that period many changes have taken place both in the treatment of this disorder and in the attitude of the medical profession toward it. The introduction of a series of antimicrobial drugs effective against all capsular types of pneumococcus has led to widespread abandonment of the more precise bacteriologic techniques designed for the recognition of this organism and secondarily to the impression that pneumococcal disease no longer constitutes a serious medical problem. To determine the validity of these practices and attitudes, established techniques for...References1. TILGHMANFINLAND RCM: Clinical significance of bacteremia in pneumococcal pneumonia. Arch. Intern. Med. (Chicago) 59: 602, 1937. CrossrefGoogle Scholar2. BULLOWA JG: The Management of the Pneumonias, Oxford University Press, New York, 1937. Google Scholar3. MACLEODAUSTRIANFINLAND CMRM: Pneumococcus, in Diagnostic Procedures and Reagents, American Public Health Association, New York, 1963, pp. 222-30. Google Scholar4. Statistical Abstract of the United States, 1958, 79th Annual Edition: U. S. Department of Commerce, Bureau of the Census, U. S. Government Printing Office, Washington, D. C., 1958, p. 6. Google Scholar5. DINGLEBADGERFELLERHODGESJORDANRAMMELKAMP JHGFAERGWSCH: A study of illness in a group of Cleveland families. I. Plan of study and certain general observations. Amer. J. Hyg. 58: 16, 1953. MedlineGoogle Scholar6. REIMANN HA: Current problems of the pneumonias. Ann. Intern. Med. 56: 144, 1962. LinkGoogle Scholar7. Advance Report, Vital Statistics of the United States, 1961. Final Natality and Mortality Statistics: National Vital Statistics Division, Department of Health, Education, and Welfare, United States Public Health Service, Nov., 1962. Google Scholar8. WOODSMITH WBMR: The inhibition of surface phagocytosis by the capsular "slime layer" of pneumococcus Type III. J. Exp. Med. 90: 85, 1949. CrossrefMedlineGoogle Scholar9. WOODSMITH WBMR: Host-parasite relationships in experimental pneumonia due to pneumococcus Type III. J. Exp. Med. 92: 85, 1950. CrossrefMedlineGoogle Scholar10. BALCH HH: Relation of nutritional deficiency in man to antibody production. J. Immun. 64: 397, 1950. MedlineGoogle Scholar11. BALCHSPENCER HHMT: Phagocytosis by human leukocytes. II. Relation of nutritional deficiency in man to phagocytosis. J. Clin. Invest. 33: 1321, 1954. CrossrefMedlineGoogle Scholar12. JETERMCKEEMASON WSAPRJ: Inhibition of immune phagocytosis of Diplococcus pneumoniae by human neutrophiles with antibody against complement. J. Immun. 86: 386, 1961. MedlineGoogle Scholar13. DOWLINGLEPPER HFMH: The effect of antibiotics (Penicillin, Aureomycin, and Terramycin) on the fatality rate and incidence of complications in pneumococcic pneumonia. Amer. J. Med. Sci. 222: 396, 1951. CrossrefMedlineGoogle Scholar14. MACLEODHODGESHEIDELBERGERBERNHARD CMRGMWG: Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides. J. Exp. Med. 82: 445, 1945. CrossrefGoogle Scholar15. KAUFMAN P: Pneumonia in old age. Arch. Intern. Med. (Chicago) 79: 518, 1947. CrossrefGoogle Scholar16. HEIDELBERGER M: Persistence of antibodies in man after immunization, in The Nature and Significance of the Antibody Response, edited by PAPPENHEIMER, A. M., JR., Columbia University Press, New York, 1953, pp. 90-101. Google Scholar17. HEIDELBERGERMACLEODDI LAPI MCMM: The human antibody response to simultaneous injection of six specific polysaccharides of pneumococcus. J. Exp. Med. 88: 369, 1948. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Philadelphia, PennsylvaniaFrom the Department of Medicine, State University of New York Downstate Medical Center, the Medical Service of Kings County Hospital, Brooklyn, New York, and the Department of Research Medicine, the University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania.These data were presented in part at the 76th Session of the Association of American Physicians, April 30, 1963.Requests for reprints should be addressed to Robert Austrian, M.D., Hospital of the University of Pennsylvania, Philadelphia 4, Pennsylvania. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByEffects of Aging and Associated Conditions on Humoral Responses to Respiratory Tract InfectionsClinical Features and Outcomes of Streptococcus pneumoniae Meningitis in Children: A Retrospective Analysis of 26 Cases in ChinaBioassay- and QSAR-based screening of toxic transformation products and their formation under chlorination treatment on levofloxacinComparing scoring systems for prediction of mortality in patients with bloodstream infectionCardiovascular complications of Streptococcus pneumoniae bacteraemiaLower Density and Shorter Duration of Nasopharyngeal Carriage by Pneumococcal Serotype 1 (ST217) May Explain Its Increased Invasiveness over Other SerotypesGastrointestinal symptoms in invasive pneumococcal disease: a cohort studyEffectiveness of Streptococcus Pneumoniae Urinary Antigen Testing in Decreasing Mortality of COVID-19 Co-Infected Patients: A Clinical InvestigationB Cell ImmunosenescenceFormulation technologies and advances for oral delivery of novel nitroimidazoles and antimicrobial peptidesPneumococcal Vaccines for Adults: What's Next?Pneumococcal VaccinesNext-Generation Whole-Cell Pneumococcal VaccinePneumococcal VaccinesInfluence of Obesity on Pneumococcus Infection Risk in the ElderlyPneumococcal Community-Acquired Pneumonia Detected by Serotype-Specific Urinary Antigen Detection AssaysEarly administration of appropriate antimicrobial agents to improve the outcome of carbapenem-resistant Acinetobacter baumannii complex bacteraemic pneumoniaA Short History of VaccinationPneumococcal Polysaccharide VaccinesA Perfect Storm: Increased Colonization and Failure of Vaccination Leads to Severe Secondary Bacterial Infection in Influenza Virus-Infected Obese MiceStreptococcus pneumoniae antimicrobial resistance decreased in the Helsinki Metropolitan Area after routine 10-valent pneumococcal conjugate vaccination of infants in FinlandTime to antibiotics administration and outcome in community-acquired pneumonia: Secondary analysis of a randomized controlled trialCombination therapy with ampicillin and azithromycin improved outcomes in a mouse model of group B streptococcal sepsisTyk2 as a target for immune regulation in human viral/bacterial pneumoniaConcurrent Infection with Hepatitis C Virus and Streptococcus pneumoniaeComparative evaluation of a newly developed 13-valent pneumococcal conjugate vaccine in a mouse modelWhite Blood Cell Counts, Alcoholism, and Cirrhosis in Pneumococcal PneumoniaResistance in Streptococcus pneumoniaeInvasive Pneumococcal Disease: Still Lots to Learn and a Need for Standardized Data Collection InstrumentsA 32-Year Study of the Effect of Pneumococcal Vaccines on Invasive Streptococcus pneumoniae DiseaseDectin-2-dependent host defense in mice infected with serotype 3 Streptococcus pneumoniaeDetermination of neutrophil CD64 expression as a prognostic biomarker in patients with community-acquired pneumoniaAntimicrobial stewardship in South Africa: a fruitful endeavourPredictive and prognostic factors in patients with blood-culture-positive community-acquired pneumococcal pneumoniaPredictors and Implications of Early Clinical Stability in Patients Hospitalized for Moderately Severe Community-Acquired PneumoniaPneumococcal Vaccination Strategies. An Update and PerspectiveThe impact of global budgeting on health service utilization, health care expenditures, and quality of care among patients with pneumonia in TaiwanAdjunctive Corticotherapy for Community Acquired Pneumonia: A Systematic Review and Meta-AnalysisMacrophage Migration Inhibitory Factor Is Detrimental in Pneumococcal Pneumonia and a Target for Therapeutic ImmunomodulationBlood culture fluorescence rates predict severity and mortality of invasive pneumococcal pneumoniaThe problem of early mortality in pneumococcal pneumonia: a study of risk factorsGlucocorticoid-Augmented Efferocytosis Inhibits Pulmonary Pneumococcal Clearance in Mice by Reducing Alveolar Macrophage Bactericidal FunctionAntibiotic resistancePneumonie – "The old man's friend"Antiinfektive Erstherapie bei SepsisAcute PneumoniaStreptococcus pneumoniaePrevention of Streptococcus pneumoniae (pneumococcal) infections in adultsAntiinfektive Erstherapie bei SepsisReasons for adult immunization – Prevention of most frequent respiratory infectionsPneumococcal Vaccine and Patients with Pulmonary DiseasesA Leukocyte Score to Improve Clinical Outcome Predictions in Bacteremic Pneumococcal Pneumonia in AdultsPneumococcal colonisation density: a new marker for disease severity in HIV-infected adults with pneumoniaVaccination anti-pneumococcique chez l'adulte : comment améliorer la couverture vaccinale ?Differences in serious clinical outcomes of infection caused by specific pneumococcal serotypes among adultsAdjunctive Corticosteroid Therapy Improves Lung Immunopathology and Survival During Severe Secondary Pneumococcal Pneumonia in MiceThe Pneumococcus: Population Biology and VirulenceThe History of Pneumococcal DiseaseHistory of Pneumococcal ImmunizationPneumococcal Pneumonia in Adults: Epidemiology, Clinical Features, Diagnosis, and TherapyPneumococcal VaccinesAttachment and Invasion of the Respiratory TractImmunodeficiency and Invasive Pneumococcal DiseaseClinical Relevance of Antibiotic Resistance in Pneumococcal InfectionsSpinal and paraspinal pneumococcal infections—a reviewImpact of the 2009 influenza A H1N1 pandemic on invasive pneumococcal disease in adultsThe Epidemiology of Alcohol Abuse and PneumoniaStreptococcal InfectionsThe complex pathogenesis of bacteremiaThe Changing Microbiologic Epidemiology of Community-Acquired PneumoniaEffect of Statin Use on Outcomes of Adults with CandidemiaFactors Influencing Early and Late Mortality in Adults with Invasive Pneumococcal Disease in Calgary, Canada: A Prospective Surveillance StudyThe Spectrum of Invasive Pneumococcal Disease in Adults in the XXI CenturyPneumococcusPneumococcal vaccination of older adultsA nationwide surveillance of invasive pneumococcal disease in adults in Israel before an expected effect of PCV7Long-term Survival Following Pneumococcal PneumoniaEstimating the Burden of Pneumococcal Pneumonia among Adults: A Systematic Review and Meta-Analysis of Diagnostic TechniquesHow Effective is Vaccination in Preventing Pneumococcal Disease?What Is the Relevance of Antimicrobial Resistance on the Outcome of Community-Acquired Pneumonia Caused by Streptococcus pneumoniae? (Should Macrolide Monotherapy Be Used for Mild Pneumonia?)The Impact of Statin and Macrolide Use on Early Survival in Patients With Pneumococcal PneumoniaLooking for new strategies to combat an old foeUnderstanding the roles of cytokines and neutrophil activity and neutrophil apoptosis in the protective versus deleterious inflammatory response in pneumoniaVaccines for preventing pneumococcal infection in adultsA short history of vaccinationPneumococcal polysaccharide vaccinesRisk factors and pathogenic significance of bacteremic pneumonia in adult patients with community-acquired pneumococcal pneumoniaRecurrent Mitral Valve Endocarditis Caused by Streptococcus pneumoniae in a Splenectomized HostTiming of antibiotic administration and outcomes of hospitalized patients with community-acquired and healthcare-associated pneumoniaBacteremia with Streptococcus pneumoniae: sepsis and other risk factors for 30-day mortality—a hospital-based cohort studyA century of pneumococcal vaccination research in humansEntendimento da mortalidade em pneumonia pneumocócica bacterêmicaImpacto de la bacteriemia en una cohorte de pacientes con neumonía neumocócicaChitinase 3-like-1 Promotes Streptococcus pneumoniae Killing and Augments Host Tolerance to Lung Antibacterial ResponsesCritical episodes in the understanding and control of epidemic meningococcal meningitisRecomendações e implementação de diretrizes sobre pneumonia adquirida na comunidade: mais problemas do que soluçõesSerotype-independent pneumococcal experimental vaccines that induce cellular as well as humoral immunityThe Anticipated Severity of a "1918-Like" Influenza Pandemic in Contemporary Populations: The Contribution of Antibacterial InterventionsBiomarqueurs et pneumonie aiguë communautaireNonmultiplying Bacteria are Profoundly Tolerant to AntibioticsWhat is different about serotype 1 pneumococci?Incidence and Cinical Characteristics of Severe Community-Acquired Pneumococcal Pneumonia: Comparisons with Non-Pneumoccocal PathogensVaccination antigrippale et antipneumococcique en pneumologie, chez l'adulte en FranceImmunomodulatory agents in the treatment of community-acquired pneumonia: A systematic reviewOutcomes of hospitalized patients with bacteraemic and non-bacteraemic community-acquired pneumonia caused by Streptococcus pneumoniaeEmerging drugs for pneumococcal pneumoniaImprovement of CRB-65 as a prognostic scoring system in adult patients with bacteraemic pneumococcal pneumoniaFactors affecting the development of systemic inflammatory response syndrome in pneumococcal infectionsDeath or survival from invasive pneumococcal disease in Scotland: associations with serogroups and multilocus sequence typesFactors Predicting Mortality in Invasive Pneumococcal Disease in Adults in AlbertaNeumonía neumocócica: cambios epidemiológicos, diagnósticos y terapéuticosWhy should we measure bacterial load when treating community-acquired pneumonia?Bacterial Polysaccharide VaccinesPneumonia in Children in Developing CountriesInfections communautaires graves — Les pneumonies aiguës communautaires bactériennes de l'adultePrise en charge des pneumonies graves à pneumocoque — Pneumonies communautaires aiguës sévères à Streptococcus pneumoniae (PAC Sp): rôle de l'hôte et des facteurs de virulence bactérienneVaccinesVaccinesInfections respiratoires basses de l'adulteDesign of clinical trials of antibacterial agents for community-acquired bacterial pneumoniaCan we predict which patients with community-acquired pneumonia are likely to have positive blood cultures?Acute Alcohol Intoxication Impairs the Hematopoietic Precursor Cell Response to Pneumococcal PneumoniaPublic health and economic impact of vaccination with 7-valent pneumococcal vaccine (PCV7) in the context of the annual influenza epidemic and a severe influenza pandemicImpact of antibiotic therapy on systemic cytokine expression in pneumococcal pneumoniaThe Spectrum of Invasive Pneumococcal Disease at an Adult Tertiary Care Hospital in the Early 21st CenturyСовременные подходы к профилактике пневмококковой инфекцииMechanisms of Neutrophil Accumulation in the Lungs Against BacteriaBacterial Infections of the Lower Respiratory TractUse of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trialOf mice and men: innate immunity in pneumococcal pneumoniaPolysaccharide VaccinesAcute PneumoniaIntroduction: PneumoniaInfections in Cirrhosis in Critical CareBacteraemic pneumococcal pneumonia in COPD patients: better outcomes than expectedRespiratory infections: A current and future threatPneumococcal Serotypes and Mortality following Invasive Pneumococcal Disease: A Population-Based Cohort StudyTreatment with Protein Synthesis Inhibitors Improves Outcomes of Secondary Bacterial Pneumonia after InfluenzaPneumococcal InfectionsResistance in Streptococcus pneumoniaeCommunity-Acquired Pneumonia Management Based on the PIRO System. A New Therapeutic ParadigmInfluence of Serotype in Pneumococcal Disease: A New Challenge for VaccinationBACTERIAL PNEUMONIASPNEUMOCOCCAL INFECTIONSAustrian's triad complicated by suppurative pericarditis and cardiac tamponade: a case report and review of the literatureEpidemiology of Invasive Pneumococcal Disease among Adult Patients in Barcelona Before and After Pediatric 7‐Valent Pneumococcal Conjugate Vaccine Introduction, 1997–2007Issues in Noninferiority Trials: The Evidence in Community‐Acquired PneumoniaPlacebo‐Controlled Trials of Treatments for Community‐Acquired Pneumonia: Review of the Literature and Discussion of Feasibility and Potential ValueWhat Can We Learn from the Time Course of Untreated and Partially Treated Community‐Onset Streptococcus pneumoniae Pneumonia? A Clinical Perspective on Superiority and Noninferiority Trial Designs for Mild Community‐Acquired PneumoniaClinical Trial Design and Selected Drug Safety Issues for Antibiotics Used to Treat Community‐Acquired PneumoniaClinical and Microbiological End Points in the Treatment of PneumoniaHistorical and Regulatory Perspectives on the Treatment Effect of Antibacterial Drugs for Community‐Acquired PneumoniaPosition Paper: Recommended Design Features of Future Clinical Trials of Antibacterial Agents for Community‐Acquired PneumoniaIs It Possible to Blind a Trial for Community‐Acquired Pneumonia?Invasive pneumococcal infections among persons with and without underlying medical conditions: Implications for prevention strategiesAnimal Models of Streptococcus pneumoniae DiseaseDelay of Active Antimicrobial Therapy and Mortality among Patients with Bacteremia: Impact of Severe NeutropeniaDoxycycline or moxifloxacin for the management of community-acquired pneumonia in the UK?Improving therapeutic strategies for secondary bacterial pneumonia following influenzaBloodstream InfectionsSystemic Expression of Cytokine Production in Patients with Severe Pneumococcal Pneumonia: Effects of Treatment with a β-Lactam versus a FluoroquinoloneAdjunctive therapies for community-acquired pneumonia: a systematic reviewTreatment and Outcomes for Patients With Bacteremic Pneumococcal PneumoniaEditorial Commentary: Reassessing the Design, Conduct, and Analysis of Clinical Trials of Therapy for Community‐Acquired PneumoniaFactors impacting on length of stay and mortality of community-acquired pneumoniaA case for immunization against nosocomial infectionsThe Presence of Pneumococcal Bacteremia Does Not Influence Clinical Outcomes in Patients With Community-Acquired PneumoniaMacrolides in Severe Community-Acquired Pneumonia and SepsisA short history of vaccinationPneumococcal polysaccharide vaccinesPneumococcusReview: Do we need new antibiotics for treating exacerbations of COPD?Ageing and InfectionA Human Monoclonal Immunoglobulin M Reduces Bacteremia and Inflammation in a Mouse Model of Systemic Pneumococcal InfectionInfluence of Neutropenia on the Course of Serotype 8 Pneumococcal Pneumonia in MiceImmunomodulation in SepsisStreptococcal InfectionsAmoxicillin Is Effective against Penicillin-Resistant Streptococcus pneumoniae Strains in a Mouse Pneumonia Model Simulating Human PharmacokineticsSevere pneumococcal pneumonia: new strategies for managementCommunity-acquired pneumonia: How far have we come?Antibiothérapie des pneumonies aiguës communautaires à Streptococcus pneumoniae : impact clinique de la résistance bactérienneAntibiotic Therapy and 48-Hour Mortality for Patients with PneumoniaOptimizing the management of community-acquired respiratory tract infections in the age of antimicrobial resistanceNon-inherited antibiotic resistanceDelayed Administration of Antibiotics and Atypical Presentation in Community-Acquired PneumoniaPrior Pneumococcal Vaccination Is Associated with Reduced Death, Complications, and Length of Stay among Hospitalized Adults with Community-Acquired PneumoniaPhenotypic Characterization of Streptococcus pneumoniae Biofilm DevelopmentPulmonary radiographic findings and mortality in hospitalized patients with lower respiratory tract infectionsPneumococcal Serotypes and VirulenceClinical experience in the management of community-acquired pneumonia: lessons from the use of fluoroquinolonesStreptococcus pneumoniae Bacteremia in Patients With CancerLiens entre résistance et échec dans les infections respiratoires communautairesProgressive and nonresolving pneumoniaThe Controversy of Combination vs Monotherapy in the Treatment of Hospitalized Community-Acquired PneumoniaWhy Do Some Patients Get Severe Pneumonia?Monotherapy versus combination antimicrobial therapy for pneumococcal pneumoniaCannula-associated Staphylococcus aureus bacteraemia: outcome in relation to treatmentAre Blood Cultures Necessary in Community-Acquired Pneumonia?Bacteremic Pneumococcal PneumoniaFactors Influencing In-hospital Mortality in Community-Acquired PneumoniaMonotherapy versus combination antimicrobial therapy for pneumococcal pneumoniaGenetic Susceptibility to PneumoniaEpidemiological differences among pneumococcal serotypesEffect of cirrhosis on antibiotic efficacy in a rat model of pneumococcal pneumoniaChemistry and Biology of Ramoplanin: A Lipoglycodepsipeptide with Potent Antibiotic ActivityProtective Levels of Polysaccharide-Specific Maternal Antibodies May Enhance the Immune Response Elicited by Pneumococcal Conjugates in Neonatal and Infant MiceIncidence of pneumococcal endocarditis: A regional health register-based study in Denmark 1981–1996Antibacterial drug resistance: implications for the treatment of patients with community-acquired pneumoniaCommunity-acquired pneumonia: pathophysiology and host factors with focus on possible new approaches to management of lower respiratory tract infectionsPersistence of antibody response to pneumococcal capsular polysaccharides in vaccinated long term-care residents in BrazilSerotype-specific mortality from invasive Streptococcus pneumoniaedisease revisitedCombination Antibiotic Therapy Lowers Mortality among Severely Ill Patients with Pneumococcal BacteremiaAntimicrobial susceptibilities and analysis of genes related to penicillin or macrolide resistance in Streptococcus pneumoniaeA review of clinical failures associated with macrolide-resistant Streptococcus pneumoniaeInvasive Pneumococcal Infections Among Hospitalized Children in Bamako, MaliPneumococcal vaccines: an update on current strategiesThe Continuing Challenge of Lower Respiratory Tract InfectionsPenicillin and Macrolide Resistance in Pneumococcal Pneumonia: Does In Vitro Resistance Affect Clinical Outcomes?Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumoniaPneumococcal Bacteremia: Lessons Learned, Yet More to LearnChanges in the Epidemiology of Pneumococcal Bacteremia in a Swiss University Hospital During a 15-Year Period, 1986-2000Nasopharyngeal Carriage of Streptococcus pneumoniae by Adults and Children in Community and Family SettingsCumulative Clinical Trial Experience with Levofloxacin for Patients with Community-Acquired Pneumonia-Associated Pneumococcal BacteremiaManagement of Community-Acquired Pneumonia Caused by Drug-Resistant Streptococcus pneumoniaeAcute Respiratory InfectionsThe Clinical Significance of Macrolide‐Resistant Streptococcus pneumoniae: It's All RelativeImmunization of Female Mice with Glycoconjugates Protects Their Offspring against Encapsulated BacteriaDrug-resistant Streptococcus pneumoniae in community-acquired pneumoniaA Testament to Sustained Macrolide EfficacyReplyBacteremic pneumococcal infections in immunocompromised patients without AIDS: the impact of β-lactam resistance on mortalityEditorial Commentary: What is Optimal Antimicrobial Therapy for Bacteremic Pneumococcal Pneumonia?Use of Pneumococcal Polysaccharide Vaccines: No Simple AnswersPneumococcal Septic Arthritis: Review of 190 CasesTesting Strategies in the Initial Management of Patients with Community-Acquired PneumoniaJoshua P. Metlay, MD, PhD and Michael J. Fine, MD, MScMacrolide‐Resistant Pneumococcal Endocarditis and Epidural Abscess that Develop during Erythromycin TherapyAging and Altered Resistance to InfectionRespuesta inflamatoria en la neumonía: ¿son útiles los glucocorticoides?International Guidelines for the Treatment of Community-Acquired Pneumonia in AdultsLa vaccination pneumococcique en France chez l'adulteThe future challenges facing the development of new antimicrobial drugsRespiratory infections: Proceedings of the Eighth Liverpool Tropical School Bayer Symposium of Microbial Disease held on 3 February 2001Historical Changes in Pneumococcal Serogroup Distribution: Implications for the Era of Pneumococcal Conjugate VaccinesFailure of Macrolide Antibiotic Treatment in Patients with Bacteremia Due to Erythromycin‐Resistant Streptococcus pneumoniaePathogenesis of Pneumococcal Pneumonia in Cyclophosphamide-Induced Leukopenia in MiceTreatment of drug-resistant pneumococcal pneumoniaPneumococcal disease in HIV-infected Malawian adults: acute mortality and long-term survivalIntranasal Immunization with Pneumococcal Conjugate Vaccines with LT-K63, a Nontoxic Mutant of Heat-Labile Enterotoxin, as Adjuvant Rapidly Induces Protective Immunity against Lethal Pneumococcal Infections in Neonatal MiceBacteremic and leukopenic pneumococcal pneumonia: successful treatment with antibiotics, pulse steroid, and continuous hemodiafiltrationEnquête nationale sur les pneumonies communautaires à pneumocoque chez des malades adultes hospitalisésOutcomes in lower respiratory tract infections and the impact of antimicrobial drug resistanceExploring the Pathogenesis of Necrotizing Fasciitis Due to Streptococcus pneumoniaeFuture vaccinesIntraabdominal Infection due to Streptococcus pneumoniaePrinciples of appropriate antibiotic use for treatment of acute respiratory tract infections in adults: Background, specific aims, and methodsPrinciples of Appropriate Antibiotic Use for Treatment of Acute Respiratory Tract Infections in Adults: Background, Specific Aims, and MethodsRalph Gonzales, MD, MSPH, John G. Bartlett, MD, Richard E. Besser, MD, Richelle J. Cooper, MD, MSHS, John M. Hickner, MD, MSc, Jerome R. Hoffman, MD, MA, and Merle A. Sande, MDBacteria and COPD Exacerbations ReduxAdjunctive Therapies in Severe Community-Acquired PneumoniaVaccination anti-pneumococcique : place et indications dans la prévention des infections communautaires des voies respiratoires inférieuresEffect of surfactant and specific antibody on bacterial proliferation and lung function in experimental pneumococcal pneumoniaThe influence of the severity of community-acquired pneumonia on the usefulness of blood culturesThe Urinary Antigen Test for the Diagnosis of Pneumococcal PneumoniaIncreasing Prevalence of Multidrug-Resistant Streptococcus pneumoniae in the United StatesManaging Antibiotic ResistancePneumococcal otitis media and pneumococcal vaccines, a historical perspectiveRisk factors for community-acquired pneumonia diagnosed upon hospital admissionInvasive pneumococcal disease in the population of VictoriaPneumococcal pneumonia and bacteremia model in mice for the analysis of protective antibodiesBacteremic and Nonbacteremic Pneumococcal Pneumonia A Prospective StudyThe Role of Bacteria in Exacerbations of COPDPulmonary infections in ventilated patients: Diagnostic and therapeutic optionsMortality from Pneumonia in Children in the United States, 1939 through 1996Early Predictors of Mortality in Pneumococcal BacteraemiaAetiology, outcome, and risk factors for mortality among adults with acute pneumonia in KenyaComparison of the Yields of Blood Cultures Using Serum or Plasma from Patients with Early Lyme DiseaseThe inevitable and continual challenge of respiratory infectionsPreparation of pneumococcal capsular polysaccharide-protein conjugate vaccines utilizing new fragmentation and conjugation technologiesAntibody response of pneumococcal vaccine: need for booster dosing?Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997Blood Cultures for Community-Acquired PneumoniaKilling of Streptococcus pneumoniae by capsular polysaccharide–specific polymeric IgA, complement, and phagocytesBacteremia in HIV-Infected Patients: Short-Term Predictors of MortalityBacteremia in HIV-Infected Patients: Short-Term Predictors of MortalityNONRESOLVING OR SLOWLY RESOLVING PNEUMONIAIntroductionTreatment of pneumococcal pneumonia: the case for penicillin GPneumococcal disease in Sweden: experiences and current situationUnusual manifestations of invasive pneumococcal infectionTherapy for pneumococcal infection at the millennium: doubts and certaintiesPneumococcal vaccines: history, current status, and future directionsPneumococcus and the Brooklyn connectionEthanol Feeding Does Not Affect the Efficacy or Pharmacokinetics of Azithromycin, Trovafloxacin, or Ceftriaxone in a Rat Model of Pneumococcal PneumoniaVaccines Against Streptococcus pneumoniaeModels of Pneumonia in Ethanol-treated RatsPneumococcal Pneumonia and Bacteremia in a Cirrhotic Rat ModelRecurrent Endocarditis Caused by Streptococcus pneumoniaePneumococcal Diversity: Considerations for New Vaccine Strategies with Emphasis on Pneumococcal Surface Protein A (PspA)Pneumococcal vaccination in HIV-1-infected adults in UgandaPulmonary sequestration of polymorphonuclear l